chr11-71444083-G-A

Variant summary

Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1

The NM_001360.3(DHCR7):​c.231C>T​(p.Thr77Thr) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0698 in 1,613,310 control chromosomes in the GnomAD database, including 4,697 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★). Synonymous variant affecting the same amino acid position (i.e. T77T) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.087 ( 649 hom., cov: 33)
Exomes 𝑓: 0.068 ( 4048 hom. )

Consequence

DHCR7
NM_001360.3 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:11

Conservation

PhyloP100: -3.98

Publications

24 publications found
Variant links:
Genes affected
DHCR7 (HGNC:2860): (7-dehydrocholesterol reductase) This gene encodes an enzyme that removes the C(7-8) double bond in the B ring of sterols and catalyzes the conversion of 7-dehydrocholesterol to cholesterol. This gene is ubiquitously expressed and its transmembrane protein localizes to the endoplasmic reticulum membrane and nuclear outer membrane. Mutations in this gene cause Smith-Lemli-Opitz syndrome (SLOS); a syndrome that is metabolically characterized by reduced serum cholesterol levels and elevated serum 7-dehydrocholesterol levels and phenotypically characterized by cognitive disability, facial dysmorphism, syndactyly of second and third toes, and holoprosencephaly in severe cases to minimal physical abnormalities and near-normal intelligence in mild cases. Alternative splicing results in multiple transcript variants that encode the same protein.[provided by RefSeq, Aug 2009]
DHCR7 Gene-Disease associations (from GenCC):
  • Smith-Lemli-Opitz syndrome
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, G2P, Myriad Women’s Health, Laboratory for Molecular Medicine, ClinGen, Labcorp Genetics (formerly Invitae)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.87).
BP6
Variant 11-71444083-G-A is Benign according to our data. Variant chr11-71444083-G-A is described in ClinVar as Benign. ClinVar VariationId is 93716.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=-3.98 with no splicing effect.
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.129 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
DHCR7NM_001360.3 linkc.231C>T p.Thr77Thr synonymous_variant Exon 4 of 9 ENST00000355527.8 NP_001351.2 Q9UBM7A0A024R5F7

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
DHCR7ENST00000355527.8 linkc.231C>T p.Thr77Thr synonymous_variant Exon 4 of 9 1 NM_001360.3 ENSP00000347717.4 Q9UBM7
DHCR7ENST00000685320.1 linkc.-333-22C>T intron_variant Intron 2 of 7 ENSP00000509319.1 B4E1K5

Frequencies

GnomAD3 genomes
AF:
0.0871
AC:
13258
AN:
152136
Hom.:
647
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.132
Gnomad AMI
AF:
0.0143
Gnomad AMR
AF:
0.0673
Gnomad ASJ
AF:
0.0889
Gnomad EAS
AF:
0.0971
Gnomad SAS
AF:
0.125
Gnomad FIN
AF:
0.0859
Gnomad MID
AF:
0.123
Gnomad NFE
AF:
0.0615
Gnomad OTH
AF:
0.0939
GnomAD2 exomes
AF:
0.0780
AC:
19441
AN:
249200
AF XY:
0.0806
show subpopulations
Gnomad AFR exome
AF:
0.136
Gnomad AMR exome
AF:
0.0365
Gnomad ASJ exome
AF:
0.0875
Gnomad EAS exome
AF:
0.0961
Gnomad FIN exome
AF:
0.0794
Gnomad NFE exome
AF:
0.0646
Gnomad OTH exome
AF:
0.0754
GnomAD4 exome
AF:
0.0680
AC:
99345
AN:
1461056
Hom.:
4048
Cov.:
30
AF XY:
0.0702
AC XY:
51043
AN XY:
726718
show subpopulations
African (AFR)
AF:
0.138
AC:
4620
AN:
33474
American (AMR)
AF:
0.0389
AC:
1738
AN:
44630
Ashkenazi Jewish (ASJ)
AF:
0.0886
AC:
2313
AN:
26112
East Asian (EAS)
AF:
0.115
AC:
4553
AN:
39670
South Asian (SAS)
AF:
0.130
AC:
11215
AN:
86038
European-Finnish (FIN)
AF:
0.0750
AC:
4000
AN:
53306
Middle Eastern (MID)
AF:
0.120
AC:
692
AN:
5766
European-Non Finnish (NFE)
AF:
0.0592
AC:
65766
AN:
1111692
Other (OTH)
AF:
0.0737
AC:
4448
AN:
60368
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.484
Heterozygous variant carriers
0
4952
9904
14856
19808
24760
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
2482
4964
7446
9928
12410
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0871
AC:
13260
AN:
152254
Hom.:
649
Cov.:
33
AF XY:
0.0893
AC XY:
6649
AN XY:
74436
show subpopulations
African (AFR)
AF:
0.132
AC:
5473
AN:
41536
American (AMR)
AF:
0.0671
AC:
1027
AN:
15304
Ashkenazi Jewish (ASJ)
AF:
0.0889
AC:
308
AN:
3466
East Asian (EAS)
AF:
0.0973
AC:
504
AN:
5180
South Asian (SAS)
AF:
0.126
AC:
607
AN:
4826
European-Finnish (FIN)
AF:
0.0859
AC:
912
AN:
10614
Middle Eastern (MID)
AF:
0.122
AC:
36
AN:
294
European-Non Finnish (NFE)
AF:
0.0615
AC:
4184
AN:
68012
Other (OTH)
AF:
0.0929
AC:
196
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.499
Heterozygous variant carriers
0
611
1222
1832
2443
3054
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
154
308
462
616
770
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0699
Hom.:
656
Bravo
AF:
0.0842
Asia WGS
AF:
0.0790
AC:
272
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:11
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Smith-Lemli-Opitz syndrome Benign:6
Feb 17, 2020
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

May 05, 2017
Natera, Inc.
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Jan 12, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

May 15, 2017
Athena Diagnostics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Feb 04, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jul 01, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not specified Benign:2
Jul 11, 2013
Eurofins Ntd Llc (ga)
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:2
Mar 03, 2015
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Inborn genetic diseases Benign:1
Mar 23, 2016
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.87
CADD
Benign
0.56
DANN
Benign
0.83
PhyloP100
-4.0
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs4316537; hg19: chr11-71155129; COSMIC: COSV62795300; COSMIC: COSV62795300; API